MA44758A - Formes cristallines de n-[2-(3-hydroxy-3-méthylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluorométhyl)pyridine-2-carboxamide - Google Patents

Formes cristallines de n-[2-(3-hydroxy-3-méthylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluorométhyl)pyridine-2-carboxamide

Info

Publication number
MA44758A
MA44758A MA044758A MA44758A MA44758A MA 44758 A MA44758 A MA 44758A MA 044758 A MA044758 A MA 044758A MA 44758 A MA44758 A MA 44758A MA 44758 A MA44758 A MA 44758A
Authority
MA
Morocco
Prior art keywords
hydroxypropan
indazol
methylbutyl
carboxamide
trifluoromethyl
Prior art date
Application number
MA044758A
Other languages
English (en)
Inventor
Nicolas Guimond
Johannes Platzek
Tobias Thaler
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA44758A publication Critical patent/MA44758A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA044758A 2016-04-29 2017-04-25 Formes cristallines de n-[2-(3-hydroxy-3-méthylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluorométhyl)pyridine-2-carboxamide MA44758A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16167649 2016-04-29
EP16167650 2016-04-29

Publications (1)

Publication Number Publication Date
MA44758A true MA44758A (fr) 2019-03-06

Family

ID=58579196

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044758A MA44758A (fr) 2016-04-29 2017-04-25 Formes cristallines de n-[2-(3-hydroxy-3-méthylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluorométhyl)pyridine-2-carboxamide

Country Status (37)

Country Link
US (2) US10501437B2 (fr)
EP (2) EP3448847A1 (fr)
JP (2) JP6821701B2 (fr)
KR (2) KR102409105B1 (fr)
CN (4) CN118184628A (fr)
AU (2) AU2017256659B2 (fr)
BR (1) BR112018072247A2 (fr)
CA (2) CA3022329A1 (fr)
CL (2) CL2018003085A1 (fr)
CO (2) CO2018011655A2 (fr)
CU (1) CU24593B1 (fr)
DK (1) DK3448849T3 (fr)
DO (1) DOP2018000236A (fr)
EA (1) EA038103B1 (fr)
EC (1) ECSP18081451A (fr)
ES (1) ES2801800T3 (fr)
GE (1) GEP20217230B (fr)
HU (1) HUE049331T2 (fr)
IL (2) IL262391B (fr)
JO (2) JOP20170101B1 (fr)
LT (1) LT3448849T (fr)
MA (1) MA44758A (fr)
MX (2) MX2018013232A (fr)
NI (1) NI201800111A (fr)
PE (2) PE20190172A1 (fr)
PH (1) PH12018502288A1 (fr)
PL (1) PL3448849T3 (fr)
PT (1) PT3448849T (fr)
RS (1) RS60419B1 (fr)
SG (2) SG11201808686VA (fr)
SI (1) SI3448849T1 (fr)
SV (1) SV2018005776A (fr)
TN (1) TN2018000359A1 (fr)
TW (3) TW201936599A (fr)
UA (2) UA122882C2 (fr)
UY (2) UY37214A (fr)
WO (2) WO2017186700A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
JP6947743B2 (ja) 2016-03-03 2021-10-13 バイエル・ファルマ・アクティエンゲゼルシャフト 新規な２−置換インダゾール、その製造方法、それを含有する医薬製剤、および薬物を製造するためのその使用
KR102373220B1 (ko) 2016-04-29 2022-03-11 바이엘 파마 악티엔게젤샤프트 인다졸의 합성
GEP20217230B (en) 2016-04-29 2021-03-10 Bayer Pharma AG Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
SG10202011653WA (en) 2016-06-01 2020-12-30 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
RU2743170C2 (ru) * 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных
EP3816164B9 (fr) 2018-06-25 2024-07-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Composé d'isothiazolo [5,4-d] pyrimidine en tant qu'inhibiteur d'irak
KR102392788B1 (ko) 2019-01-08 2022-04-28 주식회사 엘지에너지솔루션 폴더블 사이드 플레이트를 구비하는 배터리 모듈 및 그 제조 방법
CN111499612B (zh) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
CN113521079A (zh) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Irak4抑制剂在治疗ali/ards中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
AU2007213452A1 (en) 2006-02-10 2007-08-16 Biomarin Iga Limited Treatment of Duchenne muscular dystrophy
US7879887B2 (en) 2006-06-29 2011-02-01 Nissan Chemical Industries, Ltd. α-amino acid derivatives and medicaments containing the same as an active ingredient
MX2009002377A (es) 2006-09-07 2009-03-13 Biogen Idec Inc Derivados de indazol como moduladores de cinasa asociados con el receptor de interleucina-1.
US20120196824A1 (en) 2009-10-09 2012-08-02 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for cerebral infarction
WO2011153588A1 (fr) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Inhibiteurs de polymérase virale
PL2655357T3 (pl) 2010-12-20 2016-12-30 Pochodne triazolowe indazolilowe jako inhibitory irak
WO2013106254A1 (fr) 2012-01-11 2013-07-18 Dow Agrosciences Llc Compositions pesticides et procédés qui leur sont associés
WO2014086712A1 (fr) * 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh Nouveaux acides indanyloxydihydrobenzofuranylacétiques
US9126984B2 (en) * 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
US10160753B2 (en) * 2014-01-10 2018-12-25 Aurigene Discovery Technologies Limited Indazole compounds as IRAK4 inhibitors
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
CU20180006A7 (es) 2015-07-15 2018-06-05 Aurigene Discovery Tech Ltd Compuestos de indazaol y azaindazol como inhibidores de irak-4
JP6947743B2 (ja) 2016-03-03 2021-10-13 バイエル・ファルマ・アクティエンゲゼルシャフト 新規な２−置換インダゾール、その製造方法、それを含有する医薬製剤、および薬物を製造するためのその使用
EP3219329A1 (fr) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinaisons de copanlisib
KR102373220B1 (ko) 2016-04-29 2022-03-11 바이엘 파마 악티엔게젤샤프트 인다졸의 합성
GEP20217230B (en) 2016-04-29 2021-03-10 Bayer Pharma AG Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
SG10202011653WA (en) 2016-06-01 2020-12-30 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
RU2743170C2 (ru) 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных

Also Published As

Publication number Publication date
JP6821701B2 (ja) 2021-01-27
TWI671291B (zh) 2019-09-11
BR112018072213A2 (pt) 2019-02-12
CO2018011607A2 (es) 2018-11-22
US20190152944A1 (en) 2019-05-23
TWI651316B (zh) 2019-02-21
TW201738231A (zh) 2017-11-01
IL262391B (en) 2022-03-01
ES2801800T3 (es) 2021-01-13
AU2017257208B2 (en) 2022-01-20
ECSP18081451A (es) 2018-11-30
WO2017186693A1 (fr) 2017-11-02
JP6916207B2 (ja) 2021-08-11
CA3022329A1 (fr) 2017-11-02
AU2017256659A1 (en) 2018-10-25
KR102379948B1 (ko) 2022-03-31
TN2018000359A1 (en) 2020-06-15
HUE049331T2 (hu) 2020-09-28
US10501437B2 (en) 2019-12-10
CN109071491A (zh) 2018-12-21
SI3448849T1 (sl) 2020-07-31
IL262391A (en) 2018-12-31
PE20240651A1 (es) 2024-04-04
CU24593B1 (es) 2022-05-11
WO2017186700A1 (fr) 2017-11-02
KR20190002468A (ko) 2019-01-08
CL2018003085A1 (es) 2019-02-15
AU2017257208A1 (en) 2018-11-01
EP3448849B1 (fr) 2020-05-13
AU2017256659B2 (en) 2021-05-27
UY37214A (es) 2017-11-30
RS60419B1 (sr) 2020-07-31
PH12018502288A1 (en) 2019-07-15
CO2018011655A2 (es) 2018-11-13
CL2018003097A1 (es) 2019-02-15
JOP20170102B1 (ar) 2023-09-17
SV2018005776A (es) 2019-03-18
TW201936599A (zh) 2019-09-16
EA038103B1 (ru) 2021-07-06
CN109415339A (zh) 2019-03-01
BR112018072247A2 (pt) 2019-02-12
CU20180130A7 (es) 2019-06-04
PE20190172A1 (es) 2019-02-01
US10633365B2 (en) 2020-04-28
EP3448849A1 (fr) 2019-03-06
EP3448847A1 (fr) 2019-03-06
DOP2018000236A (es) 2019-01-15
MX2018013227A (es) 2019-02-13
US20190144420A1 (en) 2019-05-16
PL3448849T3 (pl) 2020-12-14
JP2019514924A (ja) 2019-06-06
CN109071491B (zh) 2020-08-21
SG11201809172WA (en) 2018-11-29
MX2018013232A (es) 2019-02-13
NI201800111A (es) 2019-08-29
IL262413A (en) 2018-12-31
IL262413B (en) 2021-05-31
UA123550C2 (uk) 2021-04-21
KR20180137498A (ko) 2018-12-27
JOP20170101B1 (ar) 2022-03-14
KR102409105B1 (ko) 2022-06-16
GEP20217230B (en) 2021-03-10
UA122882C2 (uk) 2021-01-13
EA201892407A1 (ru) 2019-05-31
JP2019514921A (ja) 2019-06-06
CA3022327A1 (fr) 2017-11-02
DK3448849T3 (da) 2020-06-29
CN112898269A (zh) 2021-06-04
SG11201808686VA (en) 2018-11-29
TW201738233A (zh) 2017-11-01
UY37217A (es) 2017-11-30
LT3448849T (lt) 2020-09-25
PT3448849T (pt) 2020-06-30
CN118184628A (zh) 2024-06-14

Similar Documents

Publication Publication Date Title
MA44758A (fr) Formes cristallines de n-[2-(3-hydroxy-3-méthylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluorométhyl)pyridine-2-carboxamide
SI3448848T1 (sl) Polimorfna oblika N-(6-(2-hidroksipropan-2-il)-2-(2-(metilsulfonil)etil)-2H-indazol-5-il) -6-(trifluormetil)piridin-2-karboksamida
DK3110418T3 (da) Aryl-, heteroaryl- og heterocykliske-forbindelser til behandling af komplemt-medierede lidelser
DK3224269T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3265085T3 (da) Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
DK3160958T3 (da) Krystallinske salte af (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidin-4-carboxamid
DK3180331T3 (da) Polymorfer af selinexor
DK3436593T3 (da) Fremgangsmåder til varmeinaktivering af adenovirus
DK3484423T3 (da) Anordning til hypertermisk behandling af kløe
DK3665296T3 (da) Fremgangsmåde med dobbeltcentrifugering til oprensning af nærende olie
MA42592A (fr) Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu'inhibiteurs de jak
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3506904T3 (da) Behandling af demens
DK3297631T3 (da) NK-1/NK-3-receptorantagonist til behandling af hedeture
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3099302T3 (da) Krystallinske former af 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidin-5-carboxamid
DK3191475T3 (da) Krystalformer af 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-n,2-dimethylbenzofuran-3-carboxamid
DK3349872T3 (da) Fremgangsmåde til kvantificering af renhed af subvisible partikelprøver
DK3529236T3 (da) Krystalformer af eravacyclin
DK3373931T3 (da) Heterocykliske forbindelser til behandling af sygdom
DK3297625T3 (da) Forbindelse til profylakse eller behandling af diabetisk nefropati eller diabetisk nyresygdom
DK3430004T3 (da) Faststofformer af nilotinibsalte
DK3624795T3 (da) Kondenserede, heteroaromatiske anilinforbindelser til behandling af hudforstyrrelser
DK3373600T3 (da) Hørehjælpeindretning til kompensering af tinnitus